Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI


Primary Symbol: V.BTI.H Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Some Thoughts in Summary
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(38)
•••
Comment by zwerp2000on Dec 27, 2022 10:28am
87 Views
Post# 35192359

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Some Thoughts in Summary

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Some Thoughts in SummaryNice post but the answer is obvious and has been for years. There is no value to XB3. Several companies "test drove" the technology but decided not to do anything with it. The company probably thought they'd find a suitor at some point but that never materialized. Even Chiesi did nothing with the XB3. Now, with the company out of money and out of funds, had no other choice but to essentially liquidate itself for next to nothing. The company had touted for years the utility of XB3 but when push came to shove, it was a complete failure. The market had been telling you this for years with the stock price being at such low levels. The game is now over and it's time to move on instead of wasting many more years on this garbage 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities